ARRHYTHMOGENIC CARDIOMYOPATHY
Clinical trials for ARRHYTHMOGENIC CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new ARRHYTHMOGENIC CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for ARRHYTHMOGENIC CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human test of gene therapy for inherited heart disease
Disease control OngoingThis is a first-in-human study to test the safety and early effectiveness of a new gene therapy called LX2020. It is for adults with a specific genetic form of arrhythmogenic cardiomyopathy, a heart condition that can cause dangerous irregular heartbeats. The therapy is given thr…
Matched conditions: ARRHYTHMOGENIC CARDIOMYOPATHY
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Experimental drug targets deadly heart rhythm disorder
Disease control TerminatedThis early-stage study is testing whether an experimental drug called IC14 can help control arrhythmogenic cardiomyopathy, a serious heart condition that causes dangerous irregular heartbeats. Five patients who already have implanted defibrillators will receive four intravenous i…
Matched conditions: ARRHYTHMOGENIC CARDIOMYOPATHY
Phase: PHASE1, PHASE2 • Sponsor: Implicit Bioscience • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Scientists track patients for years after pioneering heart gene therapy
Disease control ENROLLING_BY_INVITATIONThis study is a long-term follow-up for up to 10 patients who previously received an experimental gene therapy (LX2020) for a genetic heart muscle disease. The main goal is to monitor their health for four more years to check for any long-term side effects. No new treatment is gi…
Matched conditions: ARRHYTHMOGENIC CARDIOMYOPATHY
Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC